- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00153179
Free Fatty Acids and Vascular Function in Subjects With Diabetes
The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
During the past two decades, there has been a steady increase in the incidence of diabetes mellitus, such that nearly 17 million people are now afflicted. The vast majority of these have type 2 diabetes. Over the next 40 years, the type 2 diabetic population in the United States is expected to increase to nearly 30 million.
Diabetes substantially increases the risk of atherosclerosis, and thereby, cardiovascular morbidity and mortality. Indeed, cardiovascular disease causes more than 50% of the mortality in patients with diabetes. People with type 2 diabetes manifest two cardinal signs of dysmetabolism: hyperglycemia and insulin resistance. Insulin resistance is a progressive phenomenon that occurs well before the onset of frank diabetes, and results in alterations in insulin signaling. Experimental studies suggest that insulin signaling is required for vascular homeostasis, and its impairment is associated with endothelial dysfunction. In the clinical setting, insulin resistance is associated with atherosclerosis and predicts cardiovascular events independent of hyperglycemia. Therefore, we will study the importance of insulin signaling in endothelial biology in humans and the effects of free fatty acids on endothelial function in people with type 2 diabetes.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham & Women's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- type 2 diabetes mellitus (as defined by the National Diabetes Data Group)
- normal cardiovascular exam
- non smoker (for 1 year prior to entry)
- Healthy volunteers
- no known medical problems
- normal cardiovascular exam
- fasting glucose < 110 mg/dL
- non-smoker (for 1 year prior to entry)
Exclusion Criteria:
Type 2 Diabetics
- untreated hypertension (>140/90 mmHg)
- untreated hypercholesterolemia (LDL > 75th percentile for age)
- cigarette smoking within 1 year
- neuropathy requiring medication
- nephropathy (> 300mg/24 hour urinary albumin, or serum creatinine > 1.4 mg/dL
- abnormal cardiovascular exam
- treatment with thiazolidinedione within 1 year
- post-menopausal women taking hormone replacement therapy
(Note: subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must stop these medications for 2 weeks prior to taking study drug. If blood pressure rises to >140/90, subjects will be prescribed an alternative medication or be withdrawn from the study.
Healthy Volunteers
- abnormal cardiovascular exam
- use of prescription medications
- fasting glucose > 110mg/dL
- cigarette smoking within 1 year
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: 1
Acipimox treatment for 7 days
|
subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
Andre navne:
|
Placebo komparator: 2
placebo treatment for 7 days
|
matchende placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome
Tidsramme: 7 days
|
Flow mediated dilation is calculated as follows: A resting arterial diameter measurement is obtained using the average of 10 EKG-gated ultrasound images.
Next, an occlusive pressure is applied (using a blood pressure cuff inflated to a suprasystolic pressure)for a period of 5 minutes.
After 5 minutes, the cuff is rapidly deflated.
This produces a reactive hyperemic response which is captured via ultrasound at 1 minute post cuff deflation (also 10 EKG-gated images averaged).
The diameter of the artery following reactive hyperemia is calculated and compared to the resting diameter to obtain a percent dilation.
This is flow-mediated dilation.
|
7 days
|
Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo
Tidsramme: baseline, 7 days
|
Insulin sensitivity (M) is measured by using a hyperinsulinaemic-euglycaemic clamp.
Insulin sensitivity (M) was calculated as the average glucose infusion rate (mg/kg of body weight per min) over the last 30 min of the clamp.
Higher values indicate better outcomes (more insulin sensitive), while lower values indicate more insulin resistance.
|
baseline, 7 days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Mark Creager, M.D., Brigham and Women's Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2005P-000088
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes mellitus
-
US Department of Veterans AffairsAmerican Diabetes AssociationAfsluttetType 2 diabetes mellitusForenede Stater
-
Dexa Medica GroupAfsluttetType-2 diabetes mellitusIndonesien
-
University Hospital Inselspital, BerneAfsluttetType 2 diabetes mellitusSchweiz
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Afsluttet
-
Shanghai Zhongshan HospitalAfsluttet
-
Daewoong Pharmaceutical Co. LTD.AfsluttetT2DM (Type 2 Diabetes Mellitus)Korea, Republikken
-
Daewoong Pharmaceutical Co. LTD.AfsluttetT2DM (Type 2 Diabetes Mellitus)Korea, Republikken
-
Novartis PharmaceuticalsAfsluttetType 2 diabetes mellitus (T2DM)Forenede Stater
-
Merck Sharp & Dohme LLCAfsluttetType 2 diabetes mellitus (T2DM)
-
AstraZenecaBristol-Myers SquibbAfsluttet
Kliniske forsøg med acipimox
-
University of AarhusAfsluttet
-
Brigham and Women's HospitalAfsluttetMetabolisk syndromForenede Stater
-
University of AarhusAfsluttet
-
Maastricht University Medical CenterRekruttering
-
Medical University of ViennaAfsluttet
-
Charles University, Czech RepublicTilmelding efter invitationBulimia nervosa | Spiseforstyrrelse
-
University of AarhusAfsluttetFedme | DiabetesDanmark
-
Liverpool John Moores UniversityLiverpool University Hospitals NHS Foundation Trust; Royal Liverpool University... og andre samarbejdspartnereAfsluttetPræ-diabetesDet Forenede Kongerige
-
University of Colorado, DenverPfizer; US Department of Veterans AffairsAfsluttetEvaluering af virkningerne af en undersøgelsesmedicin på træningsfunktion ved type 2-diabetes (AcT2)Type 2 diabetesForenede Stater
-
Royal Devon and Exeter NHS Foundation TrustUniversity of ExeterAfsluttetNedsat mitokondriel funktion, muskelpræstationDet Forenede Kongerige